17th Mar 2005 07:00
Vectura Group PLC17 March 2005 Vectura Group plc Appointment of Commercial Director Chippenham, UK, 17 March 2005 - Vectura Group plc (LSE: VEC), the drugdevelopment company, today announces the appointment of Dr. Tim Wright to thenew position of Commercial Director. Dr. Wright, 43, has spent the last three and a half years with BTG plc where hewas Vice President of Business Development and Licensing within their Oncologyunit. Prior to this, Dr. Wright held management positions with GlaxoSmithKlineplc, DevCo Pharmaceuticals Limited and Simbec Research Limited. Dr. Chris Blackwell, Chief Executive of Vectura Group plc, said: "Vectura is ontrack to achieve a number of commercial objectives - our product pipeline ismaking good progress, our technologies are attracting licensing interest and ourPharmaceutical Development Services business is generating revenues. We believethat Tim's wide experience in the pharmaceutical industry, his knowledge of thedrug development process, his track record in deal-making, and his industrynetwork will allow us to deliver value-enhancing progress in the commercialarena. On behalf of the Board and the Executive, I am delighted to welcome Timto Vectura." Enquiries: Vectura Group plc Chris Blackwell, Chief Executive +44 (0) 1249 667 700 Anne Hyland, Chief Financial Officer Financial Dynamics Lucy Briggs +44 (0) 20 7831 3113 Notes to Editors: Vectura Vectura's principal focus is the development of a range of inhaled drugs for thetreatment of both lung diseases and conditions where delivery via the lungs canprovide significant benefits, such as a rapid onset of action, improved efficacyand improved tolerability compared with current therapies. The Company's strategy is to combine its proprietary pulmonary formulation anddevice technologies with existing, off-patent drugs either for use in newindications or where delivery via the lungs can provide significant benefitscompared with current therapies. The Company will seek to license its lead products to pharmaceutical companieswith established sales and marketing infrastructures for the later stages ofdevelopment and for commercialisation, typically prior to Phase III clinicaldevelopment. The Company has development collaborations with a number ofcompanies, including GSK, Chiesi and Arakis. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
VEC.L